生物医药控股 BHVN 深 沪
已收盘 07-02 16:00:00 美东时间
15.96
+0.200
+1.27%
华盛通- 最 高16.505
- 今 开15.89
- 成交量 353.07万股
- 最 低 15.60
- 昨 收 15.76
- 总市值 240.30万
- 52周最高 18.5657
- 市盈率 静 --
- 换手率 2.35%
- 52周最低 7.48
- 委 比 51.52%
- 总股本 0.00亿
- 历史最高 152.56
- 量 比 0.65
- 振 幅 5.74%
- 历史最低 7.10
- 每 手 1
- 风险率 2.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Analysts’ Top Healthcare Picks: Heart Test Laboratories, Inc. (HSCS), Biohaven Ltd. (BHVN)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
07-01 21:00
美股大行评级 | 康托·菲茨杰拉德大幅上调AMD、英特尔、迈威尔科技、美光、西部数据目标价！Applied、INIO、LFTO、Quantinuum获多家大行首予买入评级
今日重点评级关注：Evercore ISI集团：维持ProQR Therapeutics"跑赢大市"评级，目标价从5美元升至6美元；摩根士丹利：维持霍尼韦尔"标配"评级，目标价从245美元升至490美元
06-30 10:14
美股夜盘 | Abivax SA Sponsored ADR涨26.52%，航空环境涨21.56%
Abivax SA Sponsored ADR涨26.52%；航空环境涨21.56%；SharonAI Holdings, Inc. Class A涨13.58%
06-30 10:01
Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out
Biohaven Ltd. (NYSE:BHVN) shares fell Monday after Bank of America Securities (BofA) downgraded the biotechnology company, citing an unfavorable risk-reward profile ahead of a key late-stage epilepsy trial. BofA analyst Dina Ramadane downgraded Biohaven to Underperform from Neutral and lowered the p...
06-30 02:04
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Monday. Shares of Biohaven Ltd (NASDAQ:BHVN) fell sharply in pre-market trading. Biohaven announced enrollment of first patient in its pivotal Phase 3 trial of BHV-1300 for Graves’ disease. B of A Securi...
06-29 20:11
B of A Securities Downgrades Biohaven to Underperform, Lowers Price Target to $11
B of A Securities analyst Jason Gerberry downgrades Biohaven (NYSE:BHVN) from Neutral to Underperform and lowers the price target from $12 to $11.
06-29 19:44
美股夜盘 | Infleqtion, Inc.涨13.86%，D-Wave Quantum涨8.01%
Infleqtion, Inc.涨13.86%；D-Wave Quantum涨8.01%；Rigetti Computing, Inc.涨7.25%
06-23 09:01
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade Adds AbbVie deal June 22 (Reuters) - AbbVie ABBV.N has agreed to buy biotech Apogee Therapeutics APGE.O for $10.9 billion in cash, as the U.S. drugmaker builds its next-generation immunology pipeline. The move adds to a gr
06-22 19:46
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade Adds GSK deal June 9 (Reuters) - GSK GSK.L has agreed to buy cancer drug developer Nuvalent NUVL.O for $10.6 billion in its biggest deal in years, as the British drugmaker looks to bolster its pipeline and support long-ter
06-09 17:13
Biohaven Initiates First-In-Human Dosing For BHV-8100 Pyruvate Kinase M2 Isoform Modulator
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies for rare and common diseases, today
06-01 19:31
